ДІАГНОСТИКА, ЛІКУВАННЯ І ПРОФІЛАКТИКА ХРОНІЧНОГО ГЕПАТИТУ C В УМОВАХ ПЕРВИННОЇ ЛАНКИ МЕДИЧНОЇ ДОПОМОГИ (ОГЛЯД ЛІТЕРАТУРИ)
DOI:
https://doi.org/10.11603/1811-2471.2017.v0.i2.7722Ключові слова:
діагностика, лікування, хронічний гепатит, профілактика.Анотація
РЕЗЮМЕ. У статті представлений огляд літератури з діагностики, лікування та профілактики хронічного гепатиту С в умовах первинної ланки медичної допомоги.
Висвітлено питання збору анамнезу, об'єктивного дослідження, а також методи лабораторно- функціонального обстеження, що включають біохімічні маркери – визначення аланінамінотрансферази (АЛТ), аспартатамінотрансферази (АСТ), лужної фосфатази, гамма-глутамілтрансферази, альбуміну, загального білка крові, протромбінового часу, загальних показників крові; ультразвукове дослідження печінки. Для діагностики і моніторування інфекції, викликаної вірусом гепатиту C, представлені два види досліджень: серологічні – для визначення антитіл до HCV (анти-HCV), і молекулярно-біологічні – для детекції РНК вірусу (РНК HCV). Приділено особливу увагу немедикаментозним (зміна способу життя) і медикаментозним методам лікування хронічного гепатиту С у вигляді поєднання Пег-ІФН-α-2а (пегасис) і α-2b (пегінтрон) з рибавірином (копегус).
Посилання
«O merakh po sovershenstvovaniyu bor'by s virusnymi gepatitami v respublike» ["On measures to improve the fight against viral hepatitis in the republic"]. (2012). Prikaz №5 ot 5.01.2012 Ministerstvo zdravookhraneniya Respubliki Uzbekistan - Order No. 5 of 5.01.2012 Ministry of Health of the Republic of Uzbekistan [in Russian].
Alberti, A. (2006). . Lecheniye bol'nykh khronicheskim gepatitom C s iskhodno ili stoyko normal'nym urovnem ALT [Treatment of patients with chronic hepatitis C with initially or persistently normal ALT level]. Suchasnagastroyenterologíya – Modern gastroenterologiya, 2 (27), 45-54 [in Russian].
Vovk, L.M., Topolnitsky, V.S., Zaplotnaya, A.A. (2009). Khronicheskiy virusnyy gepatit C: dostizheniya v lechenii [Chronic viral hepatitis C: achievements in treatment]. Zdorov'e Ukrainy - Health of Ukraine, 1-2 (206-207), 54-55 [in Russian].
Ershov, F.I., Kasyanova, N.V. (2005). Novyye lekarstvennyye sredstva v terapii virusnykh gepatitov [New drugs in the therapy of viral hepatitis]. Consiliummedicum, 3 (1), 17-24 [in Russian].
Zaitsev, I.A. (2007). Lecheniye bol'nykh khronicheskim gepatitom C, ne otvetivshikh na protivovirusnuyu terapiyu [Treatment of patients with chronic hepatitis C who did not respond to antiviral therapy]. Suchasniinfektsii – Modern infection diseases, 4, 41-50 [in Russian].
Ivashkin, V.T. (2007). Rossiyskiy opyt primeneniya Pegasisa i Kopegusa v terapii khronicheskogo virusnogo gepatita C [The Russian experience of applying Pegasys and Copepus in the treatment of chronic viral hepatitis C]. Gastroenterologiya, gepatologiya, koloproktologiya - Gastroenterology, hepatology, coloproctology, 20 (1), 62 [in Russian].
Kharchenko, N.V. (2009). Virusnyy gepatit C: novoye v lechenii i profilaktike oslozhneniy [Viral hepatitis C: new in the treatment and prevention of complications]. Zdorov'ye Ukrainy - Health of Ukraine, 1 (6), 4 [in Russian].
Aliment Pharmacol Ther. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. The natural history of hepatitis C. (2004). Semin Liver Dis., 24, 3-8.
Anstee, Q.M., Day, C.P., (2012). S-Adenosylmethionine (SAMe) Therapy in Liver Disease: //A Review of Current Evidence and Clinical Utility, Journal of Hepatology.
Awad, T., Thorlund, K., Hauser, G., Stimac, D., Mabrouk, M., Gluud, C. (2010). Proceed with caution peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C. A systematic review of randomized trials reply. Hepatology, 52, 2241–2242.
Bartosch, B., Thimme, R., Blum, H., Zoulim, F. (2009). Hepatitis C virus-induced hepatocarcinogenesis. Hepatol., 51, 810–820.
Bisceglie, A.M. (2009). Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology, 49, 729–738.
Castera, L. (2009). Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. Viral Hepat., 16, 300–314.
Chevaliez, S., Pawlotsky, J.M. (2008). Diagnosis and management of chronic viral hepatitis: antigens, antibodies and viral genomes. Best Pract Res ClinGastroenterol., 22, 1031–1048.
Dhiman, R.K., Chawla, Y.K. (2005). Herbal medicines for liver diseases. 50(10), 1807-1812.
DeBruijne, J., Buster, E.J, Gelderblom, H.C., Brouwer, J.T., de Knegt, R.J., van Erpecum, K.J., et al. (2008). Treatment of chronic hepatitis C virus infection – Dutch national guidelines. Netherlands J Med., 66, 311–322.
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection Journal of Hepatology. (2011). 55, 245–264.
Epherd, J., Brodin, H., Cave, C., Waugh, N., Price, A., Gabbay, J. (2004) Pegylated interferon-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess., 8(39), 85-95.
Fried, M.V. (2002). Side effects of therapy of hepatitis C and their management. Hepatology, 36 (1), 237–244.
Ghany, M.G., Nelson, D.R., Strader, D.B., Thomas, D.L., Seeff, L.B. (2011). American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 54 (4), 1433-1444.
Ghany, M.G., Strader, D.B., Thomas, D.L., Seeff, L.B. American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology, 49(4), 1335-1374.
Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F. et al. (2005). Histological grading and staging of chronic hepatitis. Hepatol., 22, 696–699.
Italian Association for the study of the liver, Italian Society of infectious td, Italian Society for the study of sexually transmitted diseases. Practice guidelines for the treatment of hepatits C: recommendations from AISF/SIMIT/SIMAST. Dig Liver Dis. (2010). 42, 81–91.
Jiang, H., Wang, J., Zhao, W. (2012). Lamivudine versus telbivudine in the treatment of chronic hepatitis B: a systematic review and meta-analysis. Eur J Clin. Microbiol. Infect. Dis.
Juarres-Navarro, A., Vera-de-Leon, L., Navarro, J.et al. (2005). Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon alfa-2a ribavirin in chronic hepatitis C infection. Methods Find. Exp. Clin. Pharmacol., 27, 317–322.
Jensen, D.M., Marcellin, P., Freilich, B., Andreone, P., Di Bisceglie, A., Brandao-Mello, C.E. et al. (2009). Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha 2b a randomized trial. Ann Intern Med., 150, 97–528.
Karl-Josef Guntermann, A., Kuenker, E., Kuntz, M. (2011). Activity of essential phospholipids (EPL) from soybean in liver diseases. Review. Pharmacological reports, 63, 643-659.
Knodell, R.G., Ishak, K.G., Black, W.C., Chen, T.S., Craig, R., Kaplowitz, N. et al. (2011). Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology, 1, 431-435.
Konishi, I., Hiasa, Y., Tokumoto, Y., Abe, M., Furukawa, S., Toshimitsu, K. et al. (2011). Aerobic exercise improves insulin resistance and decreases body fat and serum levels of leptin in patients with hepatitis C virus. Hepatol.Res., 41(10), 928-935.
Liaw, Y.F., Gane, E., Leung, N., Zeuzem, S., Wang, Y., Lai, C.L. et al. (2009). 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology, 136(2), 486-495.
Lok, A.S., Heathcote, E.J., Hoofnagle, J.H. (2001). Management of Hepatitis C 2000, Summary of a Workshop. Gastroenterology, 120, 1828-1853.
Mamori, S., Suzuki, F., Bosaka, T. et al. (2004). Interferon monotherapy for patients with chrome hepatitis C and normal serum aminotransferase levels at commencement of treatment. Gastroenterol., 39, 776–782.
Management of hepatitis C. A national clinical guideline. Edinburgh (Scotland): Scottis Intercollegiate Guidelines Network (SIGN). (2006). 49.
Manns, M.P., McHutchison, J.G., Gordon, S.C.et al. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet., 358, 958–965.
МсHutchison, J., Manns, M., Patel, K.et al. (2002). Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology, 123, 1061–1069.
Muriel, P., Rivera-Espinoza, Y. (2008). Beneficial drugs for liver diseases. J Appl Toxicol., 28 (2), 93-103.
Nobili, A.A. et al. (2011). The role of lifestyle changes in the management of chronic liver disease. BMC Medicine, 9, 70.
Payen, J.L., Pillard, F., Mascarell, V., Rivière, D., Couzigou, P., Kharlov, N. (2009). Is physical activity possible and beneficial for patients with hepatitis C receiving pegylated interferon and ribavirin therapy. Gastroenterol Clin Biol., 33, 8-14.
Poynard, T., Ngo, Y., Munteanu, M., Thabut, D., Massard, J., Moussalli, J. et al. (2010). Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Antiviral Therapy, 15, 617–631.
Rauch, A., Kutalik, Z., Descombes, P., Cai, T., Di Iulio, J., Mueller, T. et al. (2010). Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome wide association study. Gastroenterology, 138, 1338–1345.
Rumi, M.G., Aghemo, A., Prati, G.M., D’Ambrosio, R., Donato, M.F., Soffredini, R. et al. (2010). Randomized study of peginterferon-alpha 2a plus ribavirin vs peginterferon-alpha 2b plus ribavirin in chronic hepatitis C. Gastroenterology, 138, 108–115.
Sarrazin, C., Berg, T., Ross, R.S., Schirmacher, P., Wedemeyer, H., Neumann, U. et al. (2010). Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection.
Seeff, L.B., Curto, T.M., Szabo, G., Everson, G.T., Bonkovsky, H.L., Dienstag, J.L. et al. (2008). HALT-C Trial Group Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology, 47(2), 605-612.
Soza, A., Everhart, J.E., Ghany, M.G. et al. (2002). Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatol., 36, 1273–1279.
Strader, D.B., Wright, T., Thomas, D.L. et al. (2004). Diagnosis, management, and treatment of hepatitis C. Hepatology, 39, 1147–1171.
Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N. et al. (2009). Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet., 41, 1105–1109.
Tassopoulos, N.C., Vanadis, I., Tsantouias, D. et al. (2002). IFN-alpha2b monotherapy in patients with chrome hepatitis C and persistently normal or near normal aminotransferase acavity; a randomized, controlled Stacy. J. Interferon Cytokine Res., 22, 365–569.
Torresi, J., Johnson, D., Wedemeyer, H. (2011). Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. Hepatol., 40, 136-144.
Thomas, R.I., Аhsan, M.B. (2001). Preventive Strategies in Chronic Liver Disease: Part I. Alcohol, Vaccines, Toxic Medications and Supplements, Diet and Exercise. American family physician, 64 (9), 201-213.
Zeuzem, S., Berg, T., Moeller, B., Hinrichsen, H., Mauss, S., Wedemeyer, H. et al. (2009). Expert opinion on the treatment of patients with chronic hepatitis C. J ViralHepat., 16, 75–90.
